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Abstract
Background: The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective 
estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-
hydroxy-N-demethyltamoxifen (4OHNDtam, endoxifen). Inter-individual variations of the activity of these enzymes due 
to polymorphisms may be predictors of outcome of breast cancer patients during tamoxifen treatment. Since 
tamoxifen and estrogens are both partly metabolized by these enzymes we hypothesize that a correlation between 
serum tamoxifen and estrogen levels exists, which in turn may interact with tamoxifen on treatment outcome. Here we 
examined relationships between the serum levels of tamoxifen, estrogens, follicle-stimulating hormone (FSH), and also 
determined the genotypes of CYP2C19, 2D6, 3A5, and SULT1A1 in 90 postmenopausal breast cancer patients.
Methods: Tamoxifen and its metabolites were measured by liquid chromatography-tandem mass spectrometry. 
Estrogen and FSH levels were determined using a sensitive radio- and chemiluminescent immunoassay, respectively.
Results: We observed significant correlations between the serum concentrations of tamoxifen, N-
dedimethyltamoxifen, and tamoxifen-N-oxide and estrogens (p < 0.05). The genotype predicted CYP2C19 activity 
influenced the levels of both tamoxifen metabolites and E1.
Conclusions: We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An 
impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed 
association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during 
tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and 
estrogen kinetics on treatment outcome are warranted.
Background
Estrogens play a key role in breast cancer development.
The selective estrogen receptor modulator (SERM)
tamoxifen has been used in breast cancer treatment and
prevention. It may act as a full estrogen agonist, partial
agonist or antagonist depending on the dose, species, sex
or target organ [1]. Tamoxifen is regarded as a pro-drug
since two of its metabolites, 4-hydroxytamoxifen
(4OHtam) and 4-hydroxy-N-demethyltamoxifen
(4OHNDtam, endoxifen), both have estrogen receptor
affinity markedly exceeding that of tamoxifen itself [2,3].
The 4OHNDtam is considered the main active metabo-
lite of tamoxifen, since it has 100-fold higher affinity for
the estrogen receptor (ER) than tamoxifen and is 10-fold
higher in serum levels than 4OHtam [4-7]. These potent
metabolites are converted from tamoxifen through the
cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5.
They are conjugated and deactivated through sulfotrans-
ferase (SULT) 1A1 [8,9] and UDP-glucuronyltransferases.
The inter-individual variations of the activity of these
enzymes due to genetic polymorphisms could therefore
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be predictors of outcome during tamoxifen treatment
considering their influence on the concentration of the
active metabolites 4OHNDtam and 4OHtam [7]. How-
ever, the results from clinical studies are partly contradic-
tory [10-20]. The conflicting results may be explained by
differences in study designs, including size, different
genetic models for the assessment of phenotypes, or dos-
ing regimens.
Tumors that initially respond to tamoxifen treatment
develop resistance over time [21]. Several mechanisms
resulting in tamoxifen resistance have been suggested.
Among others the findings of Berstein et al that long-
term exposure to tamoxifen induces hypersensitivity to
17β-estradiol (E2) suggests that E2 levels may be of
importance when resistance developes [22].
Hormonal changes involving the elevation of serum
concentrations of follicle-stimulating hormone (FSH) and
cessation of E2 levels during and after the menopause are
related to the frequency of hot flashes [23,24], which in
turn have been suggested as a predictor of tamoxifen effi-
cacy [25,26]. Patients carrying functional CYP2D6 alleles
been reported to have a higher incidence of hot flashes,
higher levels of the active metabolites of tamoxifen, and
better outcome during tamoxifen treatment [7,25,26].
Tamoxifen and estrogens are both partly metabolized
by the enzymes CYP2C19, 2D6, 3A5, and SULT1A1 (Fig-
ure 1) [27]. Therefore, we hypothesized that these geno-
types that are proposed predictors for response to
tamoxifen influence estrogen metabolism and that corre-
lations between serum tamoxifen and estrogen levels
exist. Here, we examined relationships between the
serum levels of tamoxifen, estrogens, follicle-stimulating
hormone (FSH), and sex hormone-binding globulin
(SHBG) in postmenopausal breast cancer patients. We
also determined the genotypes of CYP2C19, 2D6, 3A5,
and SULT1A1. We observed an association between
tamoxifen and its metabolites and estrogen serum levels.
The CYP2C19 predicted activity influenced both tamox-
ifen and estrogen kinetics.
Methods
Patients
From a study on tamoxifen metabolism in pre- and post-
menopausal women adjuvantly treated with tamoxifen 20
mg daily, we included exclusively postmenopausal
women in order to examine patients with stable estrogen
and FSH levels [7]. Postmenopausal status was defined as
FSH levels > 20 IU/L and E2 levels < 70 pmol/L, using the
automated analyzer Immulite 2000 (Diagnostic Products
Corporation, Los Angeles, CA). All patients with estro-
gen receptor and/or progesterone receptor-positive
tumors gave their written informed consent to participate
in the investigation. The protocol was approved by the
National Committee for Medical and Health Research
Ethics (NEM). Due to the long half-life of tamoxifen and
to ensure that these patients had reached steady-state
drug levels, only patients treated for at least 80 days were
included in the study. All patients were informed to avoid
tamoxifen ingestion on the morning of blood sampling.
Whole blood and serum samples were immediately fro-
zen and kept at -80°C until analysis.
Determination of tamoxifen and its metabolites 
concentrations
Tamoxifen citrate and 4OHtam were purchased from
Sigma-Aldrich (Steinheim, Germany), the internal stan-
dard deuterated5-tamoxifen (D5tam) and tamoxifen-N-
oxide (TamNox) from Beta Chem Inc. Life Science,
Research & Development (Kansas City, US), 4OHNDtam
from Sintef Materials and Chemistry (Oslo, Norway). N-
demethyltamoxifen (NDtam) and N-dedimethyltamox-
ifen (NDDtam) were gifts from Imperial Chemical Indus-
tries, PLC Pharmaceutical divisions (Macclesfield, UK). A
high-pressure liquid chromatography-tandem mass spec-
trometry system was used for the determination of
tamoxifen, 4OHtam, 4OHNDtam, NDtam, NDDtam and
tamNox in serum [7,28].
Determination of hormones and SHBG concentrations
FSH and SHBG levels were measured using the Immulite
2000 (Diagnostic Products Corporation, Los Angeles,
CA). Serum levels of E2, estrone (E1), and estrone sulfate
(E1S) were determined using a novel and highly sensitive
radioimmunoassay where the detection limit for E2, E1,
and E1S were 0.67 pmol/L, 1.14 pmol/L and 0.55 pmol/L,
respectively [29].
CYP2C19 genotype determination
Genomic DNA was extracted and purified from the
whole blood samples using the QIAmpR DNA Blood
Mini Kit as described in the manufacturer's (QIAmpR
DNA Blood Mini Kit) handbook (Qiagen, Hilden, Ger-
many).
CYP2C19 *2 (rs 4244285) and *3 were detected using
the LightMix assay kit (TiBMolBiol, Berlin, Germany).
CYP2C19 *17 (806C_T and 3402C_T) were determined
by DNA sequencing and hybridization probe-based real-
time PCR assay (Roche). For CYP2C19*17 (806C_T), we
used the primer 5'-AGTGGTTCTATTTAATGT-
GAAGCCT -3' (forward) and 5'-GGTCTCCCTTTC-
CCATTTG -3' (reverse). The PCR product was
bidirectionally sequenced using Big Dye Terminator ver-
sion 3.1 Cycle Sequencing kit according to the manufac-
turer's recommendations on an ABI Prism 3700 DNA
Analyzer (Applied Biosystems). The CYP2C19*17
(3402C_T) variant allele was determined by a hybridiza-
tion probe-based real-time PCR assay (Roche), using the
primer 5'-ATATCTGATAAATGATGGCTATCC-3' (for-Gjerde et al. BMC Cancer 2010, 10:313
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ward) and 5'-CTGCAAGCTAAAACCCC-3' (reverse).
The detection probe used was 5'-LC Red640-GAC-
CCGTTGCCCATTTTTTTAATCAA--PH and the
anchor probe was 5'-TGTCTTCTTGGTGAGATGTCT-
GTTC--FL (TIB MolBiol, Berlin, Germany).
CYPD6 genotype determination
Genomic leukocyte DNA was extracted from EDTA-anti-
coagulated whole blood using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany). The CYP2D6 geno-
types were tested previously and subdivided into four
Figure 1 Schematic representation of (A) tamoxifen and (B) estradiol metabolism and the enzymes involved. 4OHtam, 4-hydroxytamoxifen; 
4OHNDtam, 4-hydroxy-N-demethyltamoxifen; NDtam, N-dedimethyltamoxifen; NDDtam, N-dedimethyltamoxifen; tamNox, tamoxifen-N -oxide; CYP, 
cytochrome P450; SULT, sulfotransferase; UGT, Uridine 5'-diphospho-glucuronosyltransferase; E2, estradiol; E1, estrone; E1S, estrone sulphate; 4OHE2, 
4-hydroxyE2; 2OHE2, 2-hydroxyE2; 4MeOE2, 4-methoxyE2; 2MeOE2, 2-methoxyE2; 4OHE1, 4-hydroxyE1; 2OHE1, 2-hydroxyE1; 4MeOE1, 4-methoxyE1; 
2MeOE1, 2-methoxyE1; 16αOHE1, 16α-hydroxyE1; Catechol-O-methyl transferase, COMT. Bolded texts indicate tamoxifen and estrogen metabolizing 
enzymes investigated.
Figure 1 A 
Figure 1 B Gjerde et al. BMC Cancer 2010, 10:313
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groups and ranked according to their predicted increas-
ing enzymatic activity: poor metaboliser (PM) [subjects
with any combination of two nonfunctional variant type
(Vt) alleles *3, *4, *5 and *6], intermediate metabolizer
(IM) wild type/variant type CYP2D6, wild type/wild (Wt/
Wt) type CYP2D6, and ultra rapid metabolizer (UM)
[heterozygous Vt allele *2 × 2] [7].
CYP3A5 genotype determination
The most common CYP3A5 variant (*3) was tested to
identify patients with low CYP3A5 protein expression.
This allele is present in approximately 20% Asian, 50%
African-American, and 90% Caucasian populations. The
CYP3A5*3 variant allele was determined by a hybridiza-
tion probe-based real-time PCR assay (Roche, Germany),
using the primer 5'-TTTGCCTCTTTGTACTTCT-
TCATC-3' (forward) and 5'-TAGTTGTACGACACA-
CAGCAACC-3' (reverse). The detection probe was 5'-LC
Red640-GTTTGGACCACATTACCCTTCATC--PH and
the anchor probe was 5'-CTTTTGTCTTTCAATAT
CTCTTCCC--FL (TIB MolBiol, Berlin, Germany).
SULT1A1 genotype determination
We screened for the SULT1A1*2 variant allele with a
hybridization probe-based real-time PCR assay. To verify
these results, a PCR-based restriction fragment length
polymorphism assay and bi-directional sequencing were
used as previously published [7]. The SULT1A1 copy
number was estimated by calculating the height and area
ratio of the 210 bp amplicon of SULT1A1 to the reference
205 bp amplicon of SULT1A2 as described by Hebbring
et al [30].
Statistical analyses
CYP2C19 was sub-divided into five groups and ranked
according to their predicted increasing enzymatic activ-
ity: *2/*2 were subjects homozygous for the variant allele
CYP2C19*2, *1/*2, were subjects heterozygous for the
variant allele CYP2C19*2, homozygous wild type allele
CYP2C19*1, CYP2C19*2/*17, *1/*17 were subjects
heterozygous for the CYP2C19*17 variant allele, and *17/
*17 were subjects homozygous for the CYP2C19*17 vari-
ant allele.
CYP2D6 was sub-divided into four groups and ranked
according to their predicted increasing enzymatic activ-
ity: PM, IM, Wt/Wt, and UM. CYP3A5 was divided into
CYP3A5*3/*3 and CYP3A5*1/*3 groups. SULT1A1 geno-
type and gene dosage were also sub-divided into groups
and ranked according to their predicted increasing enzy-
matic activity: *2/*2, *1/*2 and *1/*1 and increasing copy
number, respectively. Statistical analyses were conducted
using SPSS statistical software (version 12; SPSS, USA).
All statistical tests were two-sided.
The serum levels of tamoxifen and its metabolites,
estrogens, FSH, and SHBG are given as median values
and inter-quartiles ranges. The Spearman rank correla-
tion coefficient was calculated in order to assess the asso-
ciation between two variables. Bonferroni correction was
applied to take account of multiple comparisons. All P
values were two sided. A multivariate logistic regression
model was applied. The serum levels of tamoxifen and its
metabolites (tamoxifen, 4OHtam, 4OHNDtam, NDtam,
NDDtam, and TamNox), metabolic ratios (4OHtam/tam,
tamNox/tam, NDtam/tamNox, and 4OHNDtam/
NDtam) and estrogens (E2, E1, and E1S) were dependent
variables and all genotypes (CYP2C19, CYP2D6,
CYP3A5, SULT1A1, and SULT1A1 copy number), FSH,
and SHBG were explicative variables. All tests were con-
ducted at the P = 0.05 level of significance.
Results
Patients
Ninety patients (median age 62 years) were enrolled in
this study. The median duration of tamoxifen treatment
of patients included was 571 days (Table 1). The median
[ r a n g e ]  s e ru m  c o n c e n t r a t i o n s  o f  E 2  a n d  F S H  w e r e  9 . 4
[1.3-54.7] pmol/L and 38.2 [20.3-108.0] IU/L, respec-
tively, were consistent with post-menopausal values
(Table 1). The serum level of SHBG was 81 [27-173].
Notably, we detected tamoxifen and its metabolites in all
serum samples [range 31-247 ng/ml for tamoxifen] indi-
cating good compliance for the patients included (Table
1).
Table 1: Age, duration of treatment, and biochemical and 
pharmacological parameters (n = 90)
Variables Median [Range]
Age 62 [48-85] Year
Tamoxifen duration 571 [84-4380] Days
E21 9.4 [1.3 - 54.7] pmol/L
E1 98.6 [29.3 - 355.6] pmol/L
E1S 582 [30-2923] pmol/L
FSH 38.2 [20.3 - 108.0] IU/L
SHBG 81 [27-173] nmol/L
Tam 96 [31-247] ng/ml
4OHtam 5.8 [2.7 - 17.2] ng/ml
4OHNDtam 50.7 [25.1 - 184.8] ng/ml
NDtam 230 [116-596] ng/ml
NDDtam 39.8 [15.7 - 93.4] ng/ml
tamNox 9.6 [3.5 - 37.9] ng/ml
1E2, estradiol; E1, estrone; E1S, estrone sulfate; FSH, follicle 
stimulating hormone; SHBG, sex hormone binding globulin; tam, 
tamoxifen; 4OHtam, 4-hydroxytamoxifen; 4OHNDtam, 4-
hydroxy-N-demethyltamoxifen; NDtam, N-demethyltamoxifen; 
NDDtam, N-dedimethyltamoxifen; tamNox, tamoxifen-N-oxide.Gjerde et al. BMC Cancer 2010, 10:313
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Frequencies and genotypes distribution
From a total of 90 subjects, the distribution of CYP2C19
*2/*2, *1/*2, *1/*1, heterozygous *17 (*2/*17 and *1/*17)
and *17/*17 were 4.4%, 16.7%, 38.9%, 36.7% and 3.3%,
respectively. The CYP2C19*3 allele was not detected. The
two single-nucleotide polymorphisms characterizing the
CYP2C19*17 allele (806C_T and 3402C _ T) were found
in complete linkage disequilibrium in our study popula-
tion (Table 2).
The CYP2D6 PM-, IM, Wt/Wt, and UM-genotypes dis-
tribution of the patients were 6.7%, 35.5%, 56.7%, and
1.1% respectively (Table 2). 84.4% of the patients carried
CYP3A5*3/*3 and 15.6% were CYP3A5*1/*3. The distri-
bution of SULT1A1*1/*1, SULT1A1*1/*2, and
SULT1A1*2/*2 were 48.9%, 35.5%, and 15.6% respec-
tively. Three of 90 samples (3.3%) had one copy of the
SULT1A1 gene, while 28 patients (31.1%) had three or
more copies, with the remaining subjects (65.6%) having
two copies (Table 2). Genotypes frequencies of the popu-
lation met Hardy-Weinberg equilibrium.
Table 2: CYP2C19, CYP2D6, CYP3A5, AND SULT1A1 genotype frequencies
Genotype Predicted phenotypes (n) % of total Age (median) Genotypes (n) Genotype frequency
CYP2C191 *2/*2 (4) 4.4 63 *2/*2 (4) 0.03
*1/*2 (15) 16.7 66 *1/*2 (15) 0.21
*1/*1 (35) 38.9 62 *1/*1 (35) 0.35
*1/*17 and *2/*17 (33) 36.7 62 *1/*17 (24) 0.27
*2/*17 (9) 0.08
*17/*17 (3) 3.3 65 *17/*17 (3) 0.05
CYP2D62 PM (6) 6.7 65 *4/*4 (4) 0.04
*4/*5 (2) 0.01
IM (32) 35.5 55 *1/*3 (1) 0.01
*1/*4 (27) 0.29
*1/*5 (3) 0.04
*1/*6 (1) 0.01
Wt/Wt (51) 56.7 60 *1/*1 (51) 0.48
UM (1) 1.1 50 *1/*2 ×2 (1)
CYP3A5 Vt/Vt (76) 84.4 60 *3/*3 (76) 0.85
Wt/Vt (14) 15.6 73 *1/*3 (14) 0.50
Wt/Wt (0) *1/*1 (0)
SULT1A1 Vt/Vt (14) 15.6 61 *2/*2 (14) 0.11
Wt/Vt (32) 35.5 59 *1/*2 (32) 0.44
Wt/Wt (44) 48.9 59 *1/*1 (44) 0.45
SULT1A1 copy numbers 1 (3) 3.3 59
2 (59) 65.6 60
3 (21) 23.3 67
4 (5) 5.6 72
5 (2) 2.2 69
1*2/*2, subjects homozygous for the variant allele CYP2C19*2; *1/*2, subjects heterozygous for the variant allele CYP2C19*2; intermediate 
metabolizer, subjects homozygous for the wild type allele CYP2C19*1 and with CYP2C19*2/*17; *1/*17 subjects heterozygous for the 
CYP2C19*17 variant allele; *17/*17 Vt*17 subjects homozygous for the CYP2C19*17 variant allele
2PM, poor metabolizer CYP2D6; IM, intermediate metabolizer wild type/variant type CYP2D6; Wt/Wt, wild type/wild type CYP2D6; UM, ultra rapid 
metabolizer CYP2D6.Gjerde et al. BMC Cancer 2010, 10:313
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Serum Levels of Tamoxifen, Estrogens, FSH, and SHBG
The serum levels of tamoxifen were positively associated
with the serum levels of E2 and E1 (R = 0.295, and 0.297,
p = 0.025 and p = 0.020, respectively, Table 3). A positive
association was also observed between tamoxifen and
E1S (R = 0.254, p = 0.08, Table 3), although it did not
reach a level of statistical significance. As shown in Table
3, positive associations were also observed between the
serum levels of NDDtam with E2 and E1 (R = 0.315 and R
= 0.330, p = 0.01 and p = 0.005, respectively), and tamNox
with E1 and E1S (R = 0.292 and R = 0.284, p = 0.025 and p
= 0.035, respectively). Furthermore, the serum concentra-
tion of 4OHNDtam was associated with the serum level
of FSH (R = 0.269, p = 0.05). To minimize a possible effect
of CYP2D6 allele variation and to keep a homogenous
group, this association was also examined among patients
homozygous for the CYP2D6 Wt allele (R = 0.386, p =
0.025). We also observed a negative association between
the serum level of E1S (Table 3) and SHBG (R = - 0.445, p
< 0.01).
CYP2C19 Genotype
The CYP2C19 genotype predicted enzymatic activity was
negatively associated with the serum levels of NDDtam
and tamNox (p = 0.022 and p = 0.002, respectively) as
shown in Table 4. Studying the metabolic ratios of tamox-
ifen and its metabolites, 4OHtam to tamoxifen (4OHtam/
tam) increased with increasing CYP2C19 predicted activ-
ity (p = 0.004, figure 2A) whereas no difference was
observed between CYP2C19 genotypes and the meta-
bolic ratio of 4OHNDtam to NDtam (p = 0.226, figure
2B). As for the tamNox to tamoxifen ratio was inversely
related with CYP2C19 predicted activity (p = 0.001, fig-
ure 2C). In contrast the NDtam to tamNox ratio it
increased with increasing CYP2C19 predicted activity (p
< 0.001, figure 2D).
Of the 15 individuals with predicted low CYP2C19*1/*2
enzymatic activity, 1 had CYP2D6 PM status, 5 IM status,
8 Wt/Wt status, and 1 UM status. In this CYP2C19*1/*2
subgroup, we observed no significant difference for the
4OHtam/tam ratio between the groups based on
CYP2D6 status (p = 0.932, data not shown). Furthermore,
35 individuals had CYP2C19*1/*1, of these 2 had PM sta-
tus, 11 IM status, and 22 Wt/Wt status. There was a posi-
tive association between the ratio of 4OHtam/tam and
CYP2D6 gene dose effect (p = 0.036, data not shown).
Moreover, we observed 33 individuals heterozygous for
the CYP2C19*17 allele, of these 1 with PM status, 16
CYP2D6 IM status, and 16 CYP2D6 Wt/Wt status. There
was also no significant difference for 4OHtam/tam
observed between these groups (p = 0.403). Thus, our
results suggest that CYP2D6 status does affect the ratio of
4OHtam/tam only in subjects with normal CYP2C19
activity, but not in the subjects carrying CYPC19 *17
allele.
Studying the influence of CYP2C19 genotypes on estro-
gen metabolism we observed a negative association
between increased CYP2C19 predicted enzymatic activ-
ity and E1 (Table 5). Lower serum levels of E1 was
observed in patients either heterozygous or homozygous
carriers of the CYP2C19*17 allele when compared with
patients either heterozygous or homozygous for the
CYP2C19*2 allele (p = 0.019), as shown in Table 5. No
Table 3: Associations between the serum concentrations of tamoxifen, estrogens, FSH1, and SHBG
Variables Tamoxifen 4OHtam 4OHNDtam NDtam NDDtam TamNox SHBG
A l l  ( n  =  9 0 ) rrrrrrr
E2 0.295* 0.131 0.211 0.148 0.315** 0.232 -0.048
E1 0.297* 0.133 0.152 0.226 0.330** 0.292* -0.002
E1S 0.254 0.119 0.118 0.247 0.194 0.284* -0.445**
FSH 0.118 0.065 0.269* 0.134 0.031 0.178 0.095
SHBG -0.027 0.034 0.088 0.000 0.048 0.103
Wt/Wt EM 
CYP2D6 (n = 
51)
FSH 0.151 0.133 0.386* 0.148 0.133 0.259 0.224
1FSH, Follicle Stimulating Hormone; SHBG, sex hormone binding globulin; 4OHtam, 4-hydroxytamoxifen; 4OHNDtam, 4-hydroxy-N-
demethyltamoxifen; NDtam, N-demethyltamoxifen; NDDtam, N-dedimethyltamoxifen; tamNox, tamoxifen-N-oxide; r, coefficient; E2, estradiol; 
E1, estrone; E1S, estrone sulfate; Wt/Wt EM, wild type/wild type extensive metabolizer CYP2D6.
r and p values are derived from two-tailed Spearman correlation rank test. The p-values are given after Bonferroni correction for multiple (n = 5) 
comparisons within this data set, *p < 0.05, and **p < 0.01.Gjerde et al. BMC Cancer 2010, 10:313
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CYP2C19 (data not shown).
CYP2D6 Genotype
We have shown earlier that CYP2D6 genotypes influ-
enced tamoxifen kinetics in a dose dependent manner [7].
In this sub-group of postmenopausal women, we
observed positive relations between the serum levels of
4OHtam and 4OHNDtam and CYP2D6 gene dose effect
(p = 0.019 and p = 0.009, respectively, Table 4). In con-
trast, NDtam was inversely associated with CYP2D6 pre-
dicted increasing activity (p = 0.044). We observed no
relationship between the serum levels of estrogens and
CYP2D6 genotypes (Table 5), and no associations were
observed between FSH, SHBG and CYP2D6 (data not
shown).
CYP3A5 Genotype
We also examined the association between the CYP3A5
genotypes and serum levels of tamoxifen and its metabo-
lites. The median serum concentration of tamNox was
lower for patients homozygous for the CYP3A5*3 allele
than heterozygous CYP3A5*1/*3, (p = 0.04, Table 4). The
same trend was observed in the serum levels of 4OHtam,
NDtam and NDDtam, although these did not reach sig-
nificant values (p = 0.074, p = 0.075 and p = 0.052, respec-
tively). There was no association observed between the
serum concentrations of E2, E1, E1S, and the CYP3A5
genotypes (Table 5). The same were observed between
FSH, SHBG and CYP3A5 (data not shown).
SULT1A1 Genotype
No association between the serum levels of tamoxifen
and its metabolites and the SULT1A1 genotypes was
d e m o n s t r a t e d  i n  t h i s  s u b g r o u p  o f  p o s t m e n o p a u s a l
women. The serum concentrations of E2, E1, and E1S
were not associated with SULT1A1 allele variation (Table
5). However SULT1A1 copy number was positively asso-
ciated with the serum levels of E2, E1, and E1S (p = 0.024,
p = 0.010, and p = 0.005; respectively). The SULT1A1
Figure 2 Relationships between the CYP2C19 genotype and metabolic ratios of 4OHtam/tam, 4OHNDtam/NDtam, tamNox/tam, and 
NDtam/tamNox. Error bars represent 95% confidence interval. *2/*2, encodes defective CYP2C19 activity; Vt*17, subjects heterozygous for the variant 
type allele CYP2C19*17 (*1/*17 and *2/*17); *17/*17, encodes ultra rapid CYP2C19 activity.
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Table 4: Relations between CYP2C19, CYP2D6, CYP3A5 and SULT1A1 genotypes and tamoxifen and its metabolites in postmenopausal women (n = 90)
Median concentration [q1 - q3] 1
Genotype (n) tamoxifen 4OHtam 4OHNDtam NDtam NDDtam tamNox
CYP2C192 *2/*2 (4) 107 [79 - 137] 5.1 [3.3 - 5.2] 45.7 [41.3 - 54.7] 263 [156 - 404] 47.0 [39.0 - 67.4] 12.8 [10.3 - 31.8]
*1/*2 (15) 107 [79 - 140] 5.8 [5.1 - 8.9] 61.2 [43.2 - 83.9] 233 [194 - 322] 44.8 [40.2 - 71.4] 9.7 [8.5 - 16.5]
*1/*1 (35) 92 [79 - 118] 5.5 [4.6 - 6.8] 49.6 [44.7 - 61.6] 231 [190 - 357] 38.1 [26.7 - 46.4] 9.5 [7.4 - 12.7]
Vt*17 (33) 95 [76 - 126] 6.1 [5.0 - 7.4] 53.3 [41.4 - 67.4] 229 [196 - 319] 37.8 [25.6 - 55.1] 9.1 [6.3 - 10.8]
*17/*17 (3) 154 [31 - 157] 11.3 [3.0 - 17.2] 94.3 [34.0 - 184.8] 341 [142 - 438] 36.9 [15.7 - 79.0] 11.1 [3.5 - 11.7]
P3 0.371 0.240 0.652 0.600 0.022* 0.002**
CYP2D64 PM (6) 85 [58 - 125] 4.0 [3.1 - 5.5] 37.4 [31.8 - 48.2] 296 [179 - 444] 47.0 [22.8 - 55.9] 9.2 [6.1 - 21.0]
IM (32) 87 [78 - 141] 5.9 [4.6 - 6.9] 50.5 [38.6 - 62.8] 243 [217 - 358] 38.2 [24.9 - 44.7] 9.4 [7.1 - 11.0]
Wt/Wt (51) 99 [80 - 124] 6.1 [5.0 - 8.1] 55.5 [45.7 - 69.7] 223 [117 - 299] 40.4 [33.0 - 55.6] 9.8 [7.4 - 13.4]
UM (1) 107 5.8 46.3 185 40.3 9.0
P 0.358 0.019* 0.009** 0.044* 0.413 0.958
CYP3A5 Vt/Vt (76) 96 [75 - 127] 5.6 [4.7 - 7.0] 49.9 [41.3 - 65.5] 228 [189 - 316] 38.4 [27.0 - 51.4] 9.4 [6.9 - 11.8]
Wt/Vt (14) 102 [81 - 162] 6.8 [5.7 - 10.2] 54.6 [49.4 - 80.6] 297 [221 - 396] 45.7 [32.7 - 67.3] 12.0 [9.7 - 14.5]
P 0.203 0.074 0.154 0.075 0.052 0.044*
SULT1A1 Vt/Vt (14) 91 [68 - 138] 5.5 [4.1 - 7.5] 48.6 [40.4 - 60.7] 228 [185 - 353] 37.1 [23.4 - 49.8] 9.3 [6.9 - 11.8]
Wt/Vt (32) 103 [90 - 141] 6.0 [5.1 - 7.3] 58.5 [46.2 - 75.3] 244 [201 - 361] 44.8 [37.9 - 57.6] 10.7 [8.7 - 15.2]
Wt/Wt (44) 87 [80 - 105] 5.4 [4.6 - 8.9] 51.3 [40.8 - 73.5] 219 [183 - 294] 36.9 [25.7 - 49.4] 9.0 [6.8 - 10.1]
P 0.649 0.512 0.286 0.755 0.197 0.712
SULT1A1copy 
numbers
1 (3) 84 [80 - 168] 6.7 [6.1 - 8.9] 55.1 [49.0 - 85.0] 278 [217 - 364] 37.9 [24.2 - 60.4] 9.7 [6.9 - 10.6]
2 (59) 92 [68 - 123] 5.6 [4.6 - 6.8] 50.5 [41.2 - 64.4] 227 [188 - 299] 38.4 [27.7 - 47.9] 9.4 [6.6 - 11.7]
3 (21) 107 [87 - 162] 6.9 [5.2 - 9.8] 52.7 [46.6 - 80.2] 271 [198 - 395] 46.5 [33.0 - 59.2] 9.8 [8.3 - 13.8]
4 (5) 103 [82 - 139] 5.1 [4.2 - 7.5] 58.6 [39.1 - 71.7] 223 [205 - 346] 38.1 [28.4 - 62.3] 12.7 [8.4 - 14.5]
5 (2) 86 [51 - 122] 6.2 [4.1 - 8.4] 49.2 [32.4 - 66.1] 260 [150 - 371] 45.1 [23.1 - 67.2] 11.7 [5.6 - 17.7]
P4 0.352 0.863 0.719 0.475 0.370 0.280
1Median concentration [quartile 1 - quartile 3] values of tamoxifen and metabolites are given as ng/ml.
2*2/*2, encodes defective CYP2C19 activity; Vt*17, subjects heterozygous for the variant type allele CYP2C19*17 (*1/*17 and *2/*17); *17/*17, encodes ultra rapid CYP2C19 activity.
3P values were calculated by multivariate logistic regression model, *p < 0.05. Adjusted for CYP2C19, CYP2D6, CYP3A5, SULT1A1, SULT1A1 copy number, FSH and SHBG.
4PM, poor metabolizer; IM, wild type/variant type; Wt/Wt, wild type/wild type; UM, ultra rapid metabolizer.Gjerde et al. BMC Cancer 2010, 10:313
http://www.biomedcentral.com/1471-2407/10/313
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Table 5: Relations between CYP2C19, CYP2D6, CYP3A5 and SULT1A1 genotypes and estrogens in postmenopausal 
women (n = 90)
Median concentration [q1 - q3] 1
Genotype (n) E1 E2 E1S
CYP2C192 *2/*2 (4) 122 [88 - 303] 9.6 [6.7 - 43.5] 857 [309 - 1400]
*1/*2 (15) 106 [72 - 182] 13.0 [6.6 - 32.0] 391 [234 - 955]
*1/*1 (35) 102 [70 - 124] 10.9 [5.7 - 16.0] 655 [345 - 928]
Vt*17 (33) 86 [66 - 104] 8.4 [6.0 - 12.1] 545 [259 - 801]
*17/*17 (3) 75 [54 - 122] 9.3 [9.3 - 17.4] 428 [158 - 654]
P3 0.019* 0.139 0.227
CYP2D64 PM (6) 111 [96 - 154] 9.4 [6.6 - 24.4] 491 [318 - 878]
IM (32) 91 [66 - 111] 7.7 [5.2 - 14.1] 595 [255 - 931]
Wt/Wt (51) 101 [67 - 128] 10.9 [6.1 - 17.4] 588 [345 - 888]
UM (1) 72 6.6 391
P 0.559 0.938 0.804
CYP3A5 Vt/Vt (76) 99 [71 - 123] 10.5 [6.6 - 16.4] 569 [305 - 865]
Wt/Vt (14) 97 [65 - 124] 8.0 [4.3 - 10.5] 631 [294 - 1127]
P 0.520 0.248 0.221
SULT1A1 Vt/Vt (14) 80.6 [66.4- 103.5] 6.7 [5.2- 9.4] 590.4 [316.5- 851.1]
Wt/Vt (32) 99.1 [68.6-121.7] 13.7 [5.3-18.9] 537.0 [318.0- 768.7]
Wt/Wt (44) 102.1 [70.9-142.1] 9.4 [1.4-54.7] 608.5 [135.6-2922.9]
P 0.280 0.575 0.734
SULT1A1copy numbers 1 (3) 59.7 [58.7-101.2] 3.8 [2.6- 6.5] 252.9 [235.5- 939.0]
2 (59) 89.8 [67.2-110.2] 7.7 [5.5-15.2] 498.4 [271.6- 758.9]
3 (21) 105.7 [90.7-128.6] 11.8 [9.0-14.3] 859.5 [561.3- 955.2]
4 (5) 101.8 [98.0- 103.0] 15.3 [12.6-19.1] 363.6 [227.5- 662.0]
5 (2) 157.6 [155.3-160.0] 13.6 [9.4-17.9] 2086.3 [1780.7-2391.9]
P 0.024* 0.010* 0.005**
1Median concentration [quartile 1 - quartile 3] values of tamoxifen and metabolites are given as ng/ml.
2*2/*2, encodes defective CYP2C19 activity; Vt*17, subjects heterozygous for the variant type allele CYP2C19*17 (*1/*17 and *2/*17); *17/*17, 
encodes ultra rapid CYP2C19 activity.
3P values were calculated by multivariate logistic regression model, *p < 0.05. Adjusted for CYP2C19, CYP2D6, CYP3A5, SULT1A1, SULT1A1 
copy number, FSH and SHBG.
4PM, poor metabolizer; IM, wild type/variant type; Wt/Wt, wild type/wild type; UM, ultra rapid metabolizer.
genotypes did not influence FSH and SHBG (data not
shown).
Discussion
In this study we used two highly sensitive assays for mea-
suring the serum levels of tamoxifen and its metabolites
and estrogens [28,29]. As hypothesized, we observed pos-
itive associations between the serum levels of estrogens
(E1 and E2) and tamoxifen, as well as two of its' non-
hydroxylated metabolites (NDDtam and tamNox). Inter-
estingly, the concentrations of the more potent hydroxy-
lated tamoxifen metabolites (4OHtam and 4OHNDtam)
were not correlated to estrogen levels.Gjerde et al. BMC Cancer 2010, 10:313
http://www.biomedcentral.com/1471-2407/10/313
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Metabolites of tamoxifen that are not hydroxylated may
also contribute to the effects or adverse effects of tamox-
ifen. NDtam, NDDtam and tamNox have estrogen recep-
tor affinity that is the same as for tamoxifen itself but
which is 100-fold lower than 4OHtam and 4OHNDtam
[2,31,32]. Notably, high levels of NDtam and NDDtam
have been reported in patients experiencing tamoxifen-
related side effects [33,34]. In animals NDDtam appears
to decrease the rate of tamoxifen metabolism [35]
whereas tamNox may represent a pool for its' reconver-
sion back to tamoxifen [36]. The roles of NDtam, NDD-
tam, and tamNox in the clinical situation remain to be
explored more in detail.
Dowsett et al suggests that tamoxifen effectively satu-
rates ER during tamoxifen of postmenopausal women
[31]. This may suggest that estrogen levels during tamox-
ifen therapy may have limited importance. However, long
term exposure to tamoxifen has been shown to induce a
state of adaptive hypersensitivity in breast tumors to E2
[22]. Thus, upon development of tamoxifen resistance,
low levels of estrogen may stimulate tumor growth.
Moreover, clinical studies have shown that the expression
of 17β-hydroxysteroid dehydrogenase 1 (17HSD1), which
converts E1 to the active estrogen E2, and 17HSD2, which
converts E2 to E1, are predictive factors for treatment
response to tamoxifen in both premenopausal and post-
menopausal patients [37,38]. These suggest that estrogen
levels may be of importance during long term tamoxifen
therapy.
Tamoxifen and estrogens are both partly metabolized
by the enzymes CYP2C19, 2D6, 3A5, and SULT1A1 [27].
Therefore, we screened for associations between these
genotypes and estrogen serum levels and observed that
the predicted CYP2C19 activity was related to the level of
E1. This should be expected as only E1 and not E2 or E1S
is converted by CYP2C19 (figure 1B). Patients carrying
the CYP2C19*17 allele predicting high enzyme activity
had lower serum levels of E1 compared with those carry-
ing CYP2C19 defective alleles. This finding is in agree-
ment with a recent report suggesting that an increased
catabolism of estrogens by CYP2C19 may lead to
decreased estrogen levels and therefore reduced breast
cancer risk [39], and the observation that CYP2C19*17
identifies patients likely to benefit from tamoxifen treat-
ment [19].
The 4OHtam to tamoxifen ratio was positively associ-
ated with increasing CYP2C19 predicted enzymatic
activity, whereas no such correlation was observed for the
ratio of 4OHNDtam to NDtam. This is consistent with
previous reports showing that CYP2C19 hydroxylates
tamoxifen, but not NDtam [40]. Of note is the finding
that the metabolic ratio NDtam/tamNox was highly sig-
nificantly related to the predicted activity of CYP2C19.
This is in line with the suggestion of Jordan et al that tam-
Nox represents an intermediate metabolic step between
tamoxifen and NDtam [41].
The predicted CYP2D6 and CYP3A5 activities did not
influence estrogen levels, whereas SULT1A1 gene copy
number was positively related to the levels of E2, E1, and
E1S, but not to those of tamoxifen or its metabolites. A
novel finding in the present study was the observation of
lower serum levels of tamNox in patients homozygous for
the low activity allele CYP3A5*3 compared to patients
heterozygous for this allele. Although not significant
there was also a trend for lower levels of 4OHtam,
NDtam and NDDtam. This was expected since CYP3A5
hydroxylates and demethylates tamoxifen (figure 1A).
Wegman et al observed, in contrast to Goetz et al, that
patients homozygous for CYP3A5*3 have improved
recurrence free-survival [18,25]. The clinical importance
of CYP3A5 in this matter remains unanswered.
The observed associations between the kinetics of
tamoxifen and the levels of estrogens may be due to com-
petition between tamoxifen or its metabolites and estro-
gens to be processed by identical enzymes such as
CYP2C19. An alternative explanation is that tamoxifen
and its metabolites inhibit enzymes that are involved in
the degradation of estrogens. This is line with the finding
of Meltzer et al who demonstrated that tamoxifen and
NDtam may act both competitively and non-competi-
tively on microsomal mixed function oxidases [42].
Another explanation is that the associations may also be a
consequence of the observed increase of serum levels of
dehydroepiandrosterone (DHEA) during tamoxifen treat-
ment therapy [43,44]. DHEA can be converted to andros-
tendione which is a precursor of estrogens. Both
tamoxifen and estrogens are also excreted in bile as con-
jugates. After deconjugation by intestinal microflora they
are partly reabsorbed resulting in pronounced enterohe-
patic cycling [45,46]. Accordingly, the deconjugation
capacity of the microflora in the intestines may be a com-
mon determinant for their re-absorption and bioavail-
ability [6,47].
We have observed estrogen agonistic effects of tamox-
ifen in the liver and in the pituitary gland of postmeno-
pausal patients [48]. The serum level of SHBG was more
than doubled and the level of FSH was almost halved. To
be certain that tamoxifen levels were in steady-state in
the present study all patients included were treated with
tamoxifen for at least 80 days. After this treatment period
we believe that also estrogen levels were at steady state
levels. Although tamoxifen exerts an estrogen agonistic
effect on the pituitary of postmenopausal women, we do
not know the separate effects of each of its metabolites on
the pituitary. Therefore, it is interesting that of the five
tamoxifen metabolites examined, only the serum concen-
trations of 4OHNDtam was positively associated with the
serum levels of FSH in this situation of steady-stateGjerde et al. BMC Cancer 2010, 10:313
http://www.biomedcentral.com/1471-2407/10/313
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tamoxifen kinetics. This suggests that 4OHNDtam has an
anti-estrogenic effect in the pituitary gland.
Hot flashes have been suggested as a predictor of
tamoxifen efficacy [26]. Of note, FSH serum concentra-
tions correspond better with the frequency of hot flashes
than the levels of E2 [23]. Interestingly, some results from
clinical studies suggest that patients carrying functional
CYP2D6 alleles have a higher incidence of hot flashes,
higher levels of 4OHNDtam and better outcome during
tamoxifen treatment [25,26]. Accordingly, relations
between the frequency of hot flashes, serum concentra-
tions of 4OHNDtam and outcome during tamoxifen ther-
apy may exist.
Limitations of the present study are that the correla-
tions observed are weak and we have not had admittance
to patient journals and do not know of any additional
d r u g  u s e .  H o w e v e r ,  w e  a n d  o t h e r s  h a v e  o b s e rv e d  t h a t
breast cancer patients often use several additional drugs
that may interact with tamoxifen [49-52]. Accordingly,
the weak correlations observed are not surprising as
drugs, enzymes and other factors in addition to those
analyzed in the present study may interact with the
metabolism of tamoxifen as well as that of estrogens.
Conclusions
We have shown an association between the non-hydroxy-
lated metabolites of tamoxifen and estrogen serum levels.
The influence of CYP2C19 predicted activity on tamox-
ifen and estrogen kinetics may partly explain this obser-
vation. Thus estrogens as well as tamoxifen metabolites
may influence the observed tamoxifen treatment benefit
of patients carrying CYP2C19 *17 variant. In addition,
the more potent hydroxylated tamoxifen metabolite
4OHNDtam (endoxifen) was the only tamoxifen metabo-
lite positively associated with FSH levels suggesting anti-
estrogenic effect on the pituitary. This may explain the
observed positive association between a better prognosis
and FSH levels during tamoxifen therapy. Our results
may be of importance for the effects, side effects, timing
and duration of tamoxifen treatment. Further prospective
studies to examine the effect of tamoxifen and estrogen
kinetics on treatment outcome are therefore warranted.
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